Protocol | Published:

Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers

Nature Protocols volume 7, pages 891902 (2012) | Download Citation

Abstract

Fluorescently labeled multimeric complexes of peptide-MHC, the molecular entities recognized by the T cell receptor, have become essential reagents for detection of antigen-specific CD8+ T cells by flow cytometry. Here we present a method for high-throughput parallel detection of antigen-specific T cells by combinatorial encoding of MHC multimers. Peptide-MHC complexes are produced by UV-mediated MHC peptide exchange and multimerized in the form of streptavidin-fluorochrome conjugates. Eight different fluorochromes are used for the generation of MHC multimers and, by a two-dimensional combinatorial matrix, these eight fluorochromes are combined to generate 28 unique two-color codes. By the use of combinatorial encoding, a large number of different T cell populations can be detected in a single sample. The method can be used for T cell epitope mapping, and also for the monitoring of CD8+ immune responses during cancer and infectious disease or after immunotherapy. One panel of 28 combinatorially encoded MHC multimers can be prepared in 4 h. Staining and detection takes a further 3 h.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Parallel detection of antigen-specific T cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520–526 (2009).

  2. 2.

    et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat. Protoc. 1, 1120–1132 (2006).

  3. 3.

    et al. Design and use of conditional MHC class I ligands. Nat. Med. 12, 246–251 (2006).

  4. 4.

    et al. Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc. Natl. Acad. Sci. USA 105, 3825–3830 (2008).

  5. 5.

    et al. Discovery of CD8+ T cell epitopes in Chlamydia trachomatis infection through use of caged class I MHC tetramers. Proc. Natl. Acad. Sci. USA 105, 3831–3836 (2008).

  6. 6.

    et al. Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes. J. Infect. Dis. 198, 1625–1633 (2008).

  7. 7.

    et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J. Autoimmun. 37, 151–159 (2011).

  8. 8.

    et al. Concurrent detection of circulating minor histocompatibility antigen-specific CD8 T cells in SCT recipients by combinatorial encoding MHC multimers. PLoS ONE 6, e21266 (2011).

  9. 9.

    et al. High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS ONE 6, e22523 (2011).

  10. 10.

    et al. Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes 59, 1721–1730 (2010).

  11. 11.

    et al. Dissection of T cell antigen specificity in human melanoma. Cancer Res. published online, doi:10.1158/0008-5472.CAN-11-2614 (6 February 2012).

  12. 12.

    et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. OncoImmunology 1, 1–10 (2012).

  13. 13.

    et al. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med. 2, e265 (2005).

  14. 14.

    , , & Detection of antigen-specific T cells on p/MHC microarrays. J. Mol. Recognit. 20, 32–38 (2007).

  15. 15.

    et al. Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J. Am. Chem. Soc. 131, 9695–9703 (2009).

  16. 16.

    et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332, 687–696 (2011).

  17. 17.

    , , & Simultaneous detection of many T cell specificities using combinatorial tetramer staining. Nat. Methods 6, 497–499 (2009).

  18. 18.

    et al. Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J. Immunol. Methods 340, 11–24 (2009).

  19. 19.

    & MHC multimer technology: current status and future prospects. Curr. Opin. Immunol. 17, 428–433 (2005).

  20. 20.

    et al. Quality assurance for polychromatic flow cytometry. Nat. Protoc. 1, 1522–1530 (2006).

Download references

Acknowledgements

We thank T. Seremet (Center for Cancer Immune Therapy, University Hospital Herlev) and M. Toebes (Netherlands Cancer Institute) for excellent technical assistance; and S. Walter (Immatics) and C. Gouttefangeas (Tübingen University) for supporting data on MHC multimer storage. This work was supported by the Danish Cancer Society (grant DP06031), The Danish Council for Strategic Research (grant 09-065152), the Center for Translational Molecular Medicine (grant 04I-301) and Integration of Biosynthesis and Organic Synthesis (grant 053.63.015).

Author information

Author notes

    • Sine Reker Hadrup

    Institute for International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. Present addresses: Division of Immunology and Pathogenesis, Department of Molecular and Cellular Biology, University of California, Berkeley, California, USA (A.H.B.); Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA (C.J.S.).

Affiliations

  1. Center for Cancer Immune Therapy, Department of Hematology, University Hospital Herlev, Herlev, Denmark.

    • Rikke Sick Andersen
    • , Thomas Mørch Frøsig
    • , Natasja W Pedersen
    • , Rikke Lyngaa
    • , Per thor Straten
    •  & Sine Reker Hadrup
  2. Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

    • Pia Kvistborg
    • , Arnold H Bakker
    • , Chengyi Jenny Shu
    •  & Ton N Schumacher
  3. Pharmaceutical Faculty, Department of Pharmacology and Pharmacotherapy, University of Copenhagen, Copenhagen, Denmark.

    • Thomas Mørch Frøsig

Authors

  1. Search for Rikke Sick Andersen in:

  2. Search for Pia Kvistborg in:

  3. Search for Thomas Mørch Frøsig in:

  4. Search for Natasja W Pedersen in:

  5. Search for Rikke Lyngaa in:

  6. Search for Arnold H Bakker in:

  7. Search for Chengyi Jenny Shu in:

  8. Search for Per thor Straten in:

  9. Search for Ton N Schumacher in:

  10. Search for Sine Reker Hadrup in:

Contributions

R.S.A. designed and performed experiments, analyzed data and wrote the paper; P.K. designed and performed experiments, analyzed data and co-wrote the paper; T.M.F. performed experiments and analyzed data; N.W.P. performed experiments and analyzed data; R.L. performed experiments and analyzed data; A.H.B. designed and performed experiments, and analyzed data; C.J.S. designed and performed experiments, and analyzed data; P.t.S. co-wrote the paper; T.N.S. conceived the approach, helped design experiments and co-wrote the paper; S.R.H. designed and performed experiments, analyzed data and wrote the paper.

Competing interests

The technology described in this article is the subject of a patent application. On the basis of the Netherlands Cancer Institute policy on management of intellectual property, S.R.H., A.H.B, C.J.S. and T.N.S would be entitled to a portion of received royalty income.

Corresponding author

Correspondence to Sine Reker Hadrup.

Supplementary information

PDF files

  1. 1.

    Supplementary Figure 1

    Experimental setup in 384-well microplates. When multiple MHC multimer panels are generated simultaneously, we advise the use of the outlined setup. Each row on a 384 well plate (plus 3 additional wells on a second plate) holds one full panel of 27 MHC multimers with different color codes. The exchange reaction (step 4) is conducted in 384-well microplates, numbers indicate the different peptides. After the exchange reaction is completed pMHC monomers are transferred to two new 384-well microplates (step 7) for coupling to the different fluorochrome-streptavidin conjugates (step 8). Importantly, a given pMHC complex should always maintain the same position in the plate. Finally, the MHC multimers are mixed in a new plate to obtain the final color codes (step 12), such that each well contains one pMHC complex, conjugated to two different fluorochromes. Before T-cell staining each row is mixed to generate one complete panel of 27 MHC multimers for combinatorial encoding.

  2. 2.

    Supplementary Figure 2

    Flow cytometry analysis of a T-cell population containing MART-1-reactive T cells that was either stained with MHC (HLA-A0201) multimers made with MART-1 modified peptide (left), or with MART-1 wild type peptide (right). The MART-1 wildtype peptide has a very low affinity for HLA-A0201, whereas the MART-1 modified peptide binds with high affinity. Dot plots are gated on CD8+ T cells and the MART-1-MHC multimer stained T cells are indicated in red. The panel used for this analysis had been stored at 4°C in the dark for six days prior to T-cell staining. Note that staining intensity is comparable for the two peptides.

  3. 3.

    Supplementary Table 1

    Fluorochrome specifications

  4. 4.

    Supplementary Table 2

    Typical PMT voltages for an experiment

  5. 5.

    Supplementary Table 3

    Spectral overlap values from a typical compensation made with the PMT voltages shown in Supplementary Table 2

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nprot.2012.037

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.